Evidence map›Paper›PMID 32976539›Full record

ArticlePLoS medicine2020

State-level prescription drug monitoring program mandates and adolescent injection drug use in the United States, 1995-2017: A difference-in-differences analysis.

Joel J Earlywine, Scott E Hadland, Julia Raifman

Abstract read
In one paragraph

Article in PLoS medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Joel J EarlywineDepartment of Health Law, Policy, and Management, Boston University School of Public Health, Boston, Massachusetts, United States of America.ORCID 0000-0001-6449-4327
Scott E HadlandGrayken Center for Addiction/Department of Pediatrics, Boston Medical Center, Boston, Massachusetts, United States of America.ORCID 0000-0003-3189-6199
Julia RaifmanDepartment of Health Law, Policy, and Management, Boston University School of Public Health, Boston, Massachusetts, United States of America.ORCID 0000-0001-6968-658X

Funding

Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI CURT G BECKWITH · 1998 to 2026
$51.7M
Collaborative Care Office-Based Opioid Treatment for Adolescents and Young AdultsK23DA045085 · NIDA · MASSACHUSETTS GENERAL HOSPITAL · PI HADLAND, SCOTT EVAN · 2018 to 2022
$1.1M
A Structural Approach to Improving HIV Pre-Exposure Prophylaxis (PrEP) Implementation among High Risk MenK01MH116817 · NIMH · BOSTON UNIVERSITY MEDICAL CAMPUS · PI RAIFMAN, JULIA · 2018 to 2021
$639k
NIAID NIH HHS P30 AI042853NIDA NIH HHS K23 DA045085NIDA NIH HHS L40 DA042434NIMH NIH HHS K01 MH116817
6 · The paper itself

Abstract

backgroundPrescription opioid misuse is an ongoing crisis and a risk factor for injection drug use (IDU). Few studies have evaluated strategies for preventing opioid or IDU initiation among adolescents. We evaluated changes in the proportion of adolescents reporting IDU before and after prescription drug monitoring program (PDMP) mandates were implemented in 18 states compared to 29 states without such mandates. METHODS AND

findingsThis difference-in-differences analysis used biannual Youth Risk Behavioral Surveillance System (YRBSS) data representative of adolescents 17 to 18 years old across 47 states from 1995 to 2017. We compared changes in adolescent IDU in 18 states with and 29 states without PDMP mandates. Among 331,025 adolescents, 51.7% identified as male, 62.1% as non-Hispanic white, 17.4% as non-Hispanic black, and 14.6% as Hispanic. Overall, 3.5% reported IDU during the 2 years prior to PDMP mandates. In the final multivariable difference-in-differences model, we included individual age, sex, and race/ethnicity, as well as state and year as covariates from the YRBSS. We also included state- and year-specific poverty rates based on US Census Bureau data. Additionally, we controlled for state implementation of (non-mandated) PDMPs before states subsequently implemented mandates and pill mill laws. We conducted several sensitivity analyses, including repeating our main analysis using a logistic, rather than linear, model, and with a lead indicator on PDMP mandate implementation, a lag indicator, and alternative policy implementation dates. PDMP mandates were associated with a 1.5 percentage point reduction (95% CI -2.3 to -0.6 percentage points; p = 0.001) in adolescent IDU, on average over the years following mandate implementation, a relative reduction of 42.9% (95% CI -65.7% to -17.1%). The association of PDMP mandates with this reduction persisted at least 4 years beyond implementation. Sensitivity analyses were consistent with the main results. Limitations include the multi-stepped causal pathway from PDMP mandate implementation to changes in IDU and the potential for omitted state-level time-varying confounders.

conclusionsOur analysis indicated that PDMP mandates were associated with a reduction in adolescent IDU, providing empirical evidence that such mandates may prevent adolescents from initiating IDU. Policymakers might consider PDMP mandates as a potential strategy for preventing adolescent IDU.

Indexed as

Data AnalysisAdolescentAnalgesics, OpioidFemaleHumansMaleOpioid-Related DisordersPrescription Drug Monitoring ProgramsSubstance Abuse, IntravenousUnited StatesAnalgesics, Opioid

Identifiers

PMID32976539
PMCPMC7518580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.